DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
HRS-4642: The next piece of the puzzle to keep KRAS in check
KRASG12D is the most frequent KRAS mutation in human cancer. In this issue, Zhou et al. describe a novel KRASG12D inhibitor, HRS-4642, that shows potent and selective anti-tumor activity across various models and synergizes with proteasome inhibitors. Responses have also been observed in patients during an ongoing phase 1 trial., The authors would like to acknowledge funding from the Spanish Ministry of Science and Innovation (PID2020-116705RB-100) and the Asociación Española Contra el Cáncer (LABAE211678DROS). A.A.F.-G. is supported by a CONACYT fellowship from the Mexican government., Peer reviewed